Baudax Bio Inc. (BXRX)

Full Top Line BX1000 Phase II Results Presented

April 26, 2023
Report ID: 25768
Get Report
Refer to the full report for the price target, fundamental analysis, and rating.

Equity Research provided by Noble Capital Markets is available at no cost to Registered users of Channelchek.

Already Registered? Click the ā€˜Get Reportā€™ button to login and view the research report.

Not a Member? Click ā€˜Joinā€™ or ā€˜Get Reportā€™ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

ā€Œ
Baudax Bio Inc.
Baudax Bio Inc.
Healthcare
Biotechnology
Ticker
BXRX
Price Target
Refer to Report
Volume
1.5M
52wk Range
$0.0137 - $3.4699
Related Research Reports
3/22/2024
ā€Œ
Dropping Coverage
Dropping Coverage (BXRX)
10/16/2023
ā€Œ
Shareholders Approve Merger-Related Preferred Stock Conversion
Shareholders Approve Merger-Related Preferred Stock Conversion (BXRX)
9/29/2023
ā€Œ
Orphan Drug Designation Granted By FDA for TI-168
Orphan Drug Designation Granted By FDA for TI-168 (BXRX)
8/23/2023
ā€Œ
A New Phase Begins For Baudax Bio With Reported 2Q 2023
A New Phase Begins For Baudax Bio With Reported 2Q 2023 (BXRX)

Inbox Intel from Channelchek.

Informed investors make more money. And itā€™s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
Ā© 2018-2024 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.